[Neuropeptides in the treatment of optic nerve atrophy in children]

Area of Science:

• Ophthalmology
• Neurology
• Pediatrics

Background:

• Partial optic nerve atrophy affects vision in children.
• Cerebrolysin is a potential therapeutic agent for neurological conditions.

Purpose of the Study:

• To investigate the therapeutic efficacy of cerebrolysin in pediatric patients with partial optic nerve atrophy.
• To evaluate the drug's effects based on initial vision and disease cause.

Main Methods:

• A study involving 646 children (8 weeks to 18 years) with partial optic nerve atrophy.
• Cerebrolysin administered intramuscularly (0.1 ml/kg/day) and retrobulbarly (0.3-0.5 ml).
• Treatment duration of 10-15 days, with some cases involving posterior eye segment irrigation.

Main Results:

• Positive therapeutic effects of cerebrolysin were observed.
• The drug's efficacy was particularly noted when combined with optic nerve stimulation.
• Variations in cerebrolysin's action were dependent on initial visual acuity and the etiology of the atrophy.

Conclusions:

• Cerebrolysin can be an effective treatment for partial optic nerve atrophy in children.
• The study highlights the importance of considering initial vision and disease cause for treatment personalization.
• Further research may explore optimal administration protocols and long-term outcomes.